Editas Medicine

#NEWS: Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress. Read the press release here: bit.ly/4dFI2PD. #EASCongress2026 #invivo

We’re excited to attend the 94th European Atherosclerosis Society Congress in Athens next week, where we’ll present new preclinical data on our lead in vivo development candidate, EDIT-401. For more details, read here: bit.ly/4w8kc62. #EASCongress2026 #invivo

It was a pleasure to participate in #ASGCT2026 and #TIDESUSA last week, where we were excited to share new preclinical data for our lead in vivo development candidate, EDIT-401. Thank you to everyone who spent time with the Editas team! #invivo #cardiovasculardisease #biotech

This week at #ASGCT2026, we presented new preclinical data supporting the continued advancement of our lead in vivo development candidate, EDIT-401, as well as the broader potential of our differentiated upregulation strategy. View the presentations here: bit.ly/3RbSqFI.

Join us today as we present new preclinical data from our lead in vivo development candidate, EDIT-401, in an oral presentation at #ASGCT2026. #invivogeneediting #cardiovasculardisease #biotechnology

#NEWS: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting. Read the press release for details: bit.ly/4dIHHve. #ASGCT2026 #invivo

Today we’re at the TIDES USA 2026 Meeting, where we’ll be sharing more information on our lead in vivo development candidate, EDIT-401, in an oral presentation. For details, visit the TIDES website: bit.ly/4neYOIi. #TIDESUSA #invivo #geneediting #cardiovasculardisease

Attending ASGCT? Check out our posters featured during the Wednesday and Thursday Poster Receptions from 5:00 p.m. – 6:30 p.m. EDT in the Exhibit and Poster Hall. For more information on the presentations, read here: bit.ly/4w8kc62. #ASGCT2026 #geneediting #healthcare

This week, we’ll be presenting new preclinical data at the American Society of Gene and Cell Therapy and TIDES USA annual meetings. For more details on our presence at each conference, read here: bit.ly/4w8kc62. #ASGCT2026 #TIDESUSA #invivo #cardiovasculardisease

Yesterday, Editas Medicine announced first quarter 2026 results and business updates. Read the full press release here: bit.ly/4cSmNcM. #geneediting #biotech #cardiovasculardisease #hyperlipidemia

#NEWS: Editas Medicine Announces First Quarter 2026 Results and Business Updates. For more details, read the full press release here: bit.ly/4cSmNcM #invivo #cardiovasculardisease #geneediting #earnings

#NEWS: Editas Medicine to Present New Preclinical Data at Upcoming Scientific Conferences. For more details, read the full press release here: bit.ly/4udm37J #invivo #geneediting #cardiovascular #ASGCT2026 #TIDESUSA #EASCongress2026

Editas presented at the 5th Lipid Nanoparticle Formulation & Process Development Summit, sharing insights on consistent, scalable LNP manufacturing through optimized mixing processes. We're proud to contribute to conversations shaping the future of gene editing. #geneediting #LNP

#News: Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference. Read the full press release here: bit.ly/4bPrSRw #invivogeneediting #biotechnology #CRISPR

#NEWS: Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates. For more details, read the full press release here: bit.ly/4stTz8X #biotech #geneediting #earnings

#News: Editas Medicine to Participate in Upcoming Investor Conferences. For more details, read the full press release here: bit.ly/46oArAO #invivogeneediting #biotechnology #healthcare

Gilmore O’Neill joined the Let's Talk About That podcast to discuss the future of in vivo gene editing and EDIT-401, an experimental, potential best-in-class, one-time therapy that has achieved ≥90% mean LDL cholesterol reduction in NHPs. Listen here: bit.ly/4k3RHko

#NEWS: Editas Medicine Announces Third Quarter 2025 Results and Business Updates. For more details, read the full press release here: bit.ly/43XeZ4z #biotech #earnings

#NEWS: Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025. For more details, read the full press release here: bit.ly/4qUoXh8 #geneediting #biotech

#NEWS: Editas Medicine Reports In Vivo Proof-Of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress: bit.ly/4q7HKoM #invivogeneediting #geneediting